These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 22843906

  • 1. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.
    Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
    [Abstract] [Full Text] [Related]

  • 2. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.
    Cancer; 2011 Jun 01; 117(11):2419-25. PubMed ID: 24048789
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 01; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 4. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.
    Anticancer Res; 2012 Feb 01; 32(2):633-41. PubMed ID: 22287756
    [Abstract] [Full Text] [Related]

  • 5. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.
    Clin Cancer Res; 2008 Oct 01; 14(19):6270-6. PubMed ID: 18829508
    [Abstract] [Full Text] [Related]

  • 6. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov 01; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):293-303. PubMed ID: 22752248
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):6-14. PubMed ID: 22340631
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.
    Hervonen P, Jekunen A, Lefebvre P, Kellokumpu-Lehtinen P.
    Int J Clin Pharmacol Res; 2003 Mar 01; 23(1):1-7. PubMed ID: 14621067
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA.
    J Clin Oncol; 2010 Sep 20; 28(27):4247-54. PubMed ID: 20733135
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T.
    Anticancer Res; 2009 Feb 20; 29(2):769-75. PubMed ID: 19331234
    [Abstract] [Full Text] [Related]

  • 19. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, Filleur S, Allhoff EP.
    Onkologie; 2005 Nov 20; 28(11):573-8. PubMed ID: 16249643
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.